AN2 Therapeutics Inc
ANTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$137.01M
Close$
$0.66
86.7% downside
Current Fair Value
86.7% downsideOvervalued by 86.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $137.01 Million |
|---|---|
| Enterprise Value | $83.52 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.16 |
| Beta | -0.98 |
| Outstanding Shares | 34,059,876 |
Return
| Return on Equity | -42.26% |
|---|---|
| Return on Assets | -39.49% |
| Return on Invested Capital | -44.67% |
Valuation & Multiples
| P/E Ratio | -4.55 |
|---|---|
| PEG | 77.95 |
| Price to Sales | - |
| Price to Book Ratio | 2.49 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -2.28 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$-0.23
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.23
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 72.46%▲ 43.84% |
|---|---|
| Total Invested | $74.78M▲ 657.03% |
| Investors Holding | 52▲ 15.00% |
ESG Score
No data